For citations:
Rumyantsev A.A., Protasova A.E., Grechkina A.A., Volkonskiy M.V., Mukhitova M.R., Aymamedova O.N., Goryainova A.Yu., Akopyan A.A., Gofman A.A., Zhelezkova T.A., Zhikhorev R.S., Krasnorutskaya E.P., Abidova N.R., Makarkina T.A., Sisakyan V.G., Skorina M.O., Filippova V.M., Chebodaev A.K., Chernorubashkina N.M., Medvedev S.P., Bubenko D.N., Antipin A.S., Vasilyeva Yu.V., Goloschapova N.S., Gonchikov B.V., Davydova T.V., Khodareva D.V., Karpovich M.P., Krashihina T.V., Lots I.Yu., Magomedova E.M., Milyukova A.O., Nazranova S.T., Musaeva N.E., Prokudina N.V., Rabadanova P.R., Romanova N.D., Romanchuk O.V., Sakulin P.A., Skotnikov R.A., Sunyaykin A.B., Tabakova A.I., Talalaeva E.A., Titov K.V., Tonenkova E.E., Trushina Yu.A., Usoltseva I.S., Khabrieva Kh.M., Tsarakhova F.V., Shakhnovich E.B., Shishkov A.P., Letuchikh A.N. Efficacy and safety of lenvatinib plus pembrolizumab in patients with endometrial cancer: data from an extended study of routine clinical practice in Russia. Tumors of female reproductive system. 2024;20(4):111-118. (In Russ.) https://doi.org/10.17650/1994-4098-2024-20-4-111-118
Email this article 